Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Sankhala on the Significance of TRC105/Pazopanib in Angiosarcoma

Kumar Sankhala, MD
Published: Monday, Apr 10, 2017



Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses the significance of the combination of the endoglin antibody TRC105 plus pazopanib (Votrient) in patients with angiosarcoma.

Angiosarcoma is a challenging subtype of sarcoma that is also very aggressive, Sankhala explains. There are some chemotherapy options used to treat these patients, including paclitaxel and doxorubicin. While patients do respond to the chemotherapy, their disease recurs and progresses quickly, he adds.

With the discovery of TRC105, researchers predict that this will achieve prolonged stabilization of responses in these patients, Sankhala explains.


Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses the significance of the combination of the endoglin antibody TRC105 plus pazopanib (Votrient) in patients with angiosarcoma.

Angiosarcoma is a challenging subtype of sarcoma that is also very aggressive, Sankhala explains. There are some chemotherapy options used to treat these patients, including paclitaxel and doxorubicin. While patients do respond to the chemotherapy, their disease recurs and progresses quickly, he adds.

With the discovery of TRC105, researchers predict that this will achieve prolonged stabilization of responses in these patients, Sankhala explains.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x